Merck: CHMP nods pneumococcal vaccine

(CercleFinance.com) - On Friday Merck announced that it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on its application for marketing authorisation for its pneumococcal vaccine in babies, children and adolescents.


In a statement, the US pharmaceutical company said the European Commission's marketing authorisation is expected by the end of the year.

The vaccine, called Vaxneuvance, had already received marketing authorisation in the European Union for adults over the age of 18.

It is now indicated for the active immunisation of infants, children and adolescents aged six weeks to 17 years to prevent invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia) caused by serotypes of Streptococcus pneumoniae.


Copyright (c) 2022 CercleFinance.com. All rights reserved.